Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by RPINVESTOR1on Mar 19, 2024 1:32pm
67 Views
Post# 35941025

RE:Only hope is YOFOTO. or Second LOI by others.....

RE:Only hope is YOFOTO. or Second LOI by others.....Baldstock:-

I don't think anyone on the Board of Directors should be allowed to vote on this proposal. This is one big conflict of interest. For example, does anyone really believe that Jamie Mackay with a little more than 10 million shares (15.44% of the float) will be content to receive 8% of 15.44% (1.23%) of any revenue generated ('after expenses') from sales and/or royalties? 

Four of the other Directors also have between 300,000 and 900,000 shares (Buckler has only 6,808 shares). I do not believe that there is any way these Directors would approve this deal unless Andrew Schutte is going to 'look after them' after the spotlight has been turned off. I believe that the '92%' includes a portion which will go to these individuals. 

I have reached out to YOFOTO's Larissa Huang  (a former Replicel Director) in an attempt to get her position on the offer. I await her reply. YOFOTO is in a more complicated situation as I'm not sure how the success or rejection of this offer might affect their efforts to conduct the tendon trials and the introduction of the dermal device in China. On the other hand, they have about 6 million shares whose potential value upon acceptance of this offer will be greatly reduced - unless they are also part of the '92% Club!'
 

    
<< Previous
Bullboard Posts
Next >>